Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

The 25 analysts with 12-month price forecasts for REGN stock have an average target of 1,024, with a low estimate of 165 and a high estimate of 1,300. The average target predicts an increase of 50.28% from the current stock price of 681.58.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$165	$1,024	$1,099	$1,300
Change	-75.79%	+50.28%	+61.24%	+90.73%

Analyst Ratings

The average analyst rating for REGN stock from 25 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Aug '24	Sep '24	Oct '24	Nov '24	Dec '24	Jan '25
Strong Buy	8	8	8	8	6	6
Buy	11	11	11	12	12	12
Hold	4	5	4	4	5	6
Sell	1	1	1	0	1	1
Strong Sell	0	0	0	0	0	0
Total	24	25	24	24	24	25

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Trung Huynh UBS	UBS	Strong Buy → Hold Downgrades $1,130 → $738	Strong Buy → Hold	Downgrades	$1,130 → $738	+8.28%	Jan 16, 2025
Geoff Meacham Citigroup	Citigroup	Hold Maintains $895 → $795	Hold	Maintains	$895 → $795	+16.64%	Jan 14, 2025
Mohit Bansal Wells Fargo	Wells Fargo	Buy Maintains $1,050 → $900	Buy	Maintains	$1,050 → $900	+32.05%	Jan 10, 2025
Srikripa Devarakonda Truist Securities	Truist Securities	Strong Buy Maintains $1,126 → $1,004	Strong Buy	Maintains	$1,126 → $1,004	+47.30%	Jan 8, 2025
William Pickering Bernstein	Bernstein	Buy Maintains $1,110 → $1,070	Buy	Maintains	$1,110 → $1,070	+56.99%	Jan 7, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

14.46B

Increased by 10.24%

from 13.12B

Revenue Next Year

15.08B

Increased by 4.30%

from 14.46B

EPS This Year

45.86

Increased by 31.88%

from 34.77

EPS Next Year

45.94

Increased by 0.18%

from 45.86

Fiscal Year	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	6.56B	8.50B	16.07B	12.17B	13.12B	14.46B	15.08B	16.09B
Revenue Growth	27.44%	29.58%	89.14%	-24.26%	7.76%	10.24%	4.30%	6.65%
EPS	18.46	30.52	71.97	38.22	34.77	45.86	45.94	51.67
EPS Growth	-13.29%	65.33%	135.81%	-46.89%	-9.03%	31.88%	0.18%	12.47%
Forward PE	-	-	-	-	-	14.86	14.84	13.19
No. Analysts	-	-	-	-	-	31	31	25

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2024	2025	2026	2027	2028	2029
High	15.3B	17.0B	19.0B
Avg	14.5B	15.1B	16.1B
Low	13.6B	13.3B	14.2B

Revenue Growth

Revenue Growth	2024	2025	2026	2027	2028	2029
High	16.4%	17.4%	25.8%
Avg	10.2%	4.3%	6.6%
Low	3.3%	-7.7%	-5.6%

EPS Forecast

EPS	2024	2025	2026	2027	2028	2029
High	49.55	54.55	67.06
Avg	45.86	45.94	51.67
Low	41.94	34.63	41.03

EPS Growth

EPS Growth	2024	2025	2026	2027	2028	2029
High	42.5%	19.0%	46.0%
Avg	31.9%	0.2%	12.5%
Low	20.6%	-24.5%	-10.7%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.